share_log

Liaoning OxiranchemInc (SZSE:300082) Shareholders Are up 16% This Past Week, but Still in the Red Over the Last Three Years

Liaoning OxiranchemInc (SZSE:300082) Shareholders Are up 16% This Past Week, but Still in the Red Over the Last Three Years

辽宁OxiranCheminc(深圳证券交易所代码:300082)股东上周上涨了16%,但在过去三年中仍处于亏损状态
Simply Wall St ·  04/30 01:26

Liaoning Oxiranchem,Inc. (SZSE:300082) shareholders should be happy to see the share price up 16% in the last week. But that doesn't help the fact that the three year return is less impressive. After all, the share price is down 41% in the last three years, significantly under-performing the market.

辽宁奥西兰化工股份有限公司(深圳证券交易所股票代码:300082)的股东应该很高兴看到上周股价上涨了16%。但这无助于三年回报率不那么令人印象深刻的事实。毕竟,股价在过去三年中下跌了41%,表现大大低于市场。

The recent uptick of 16% could be a positive sign of things to come, so let's take a look at historical fundamentals.

最近16%的上涨可能是即将发生的事情的积极信号,所以让我们来看看历史基本面。

Liaoning OxiranchemInc wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. When a company doesn't make profits, we'd generally hope to see good revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

辽宁OxiRancheminc在过去十二个月中没有盈利,我们不太可能看到其股价与每股收益(EPS)之间存在很强的相关性。可以说,收入是我们的下一个最佳选择。当一家公司没有盈利时,我们通常希望看到良好的收入增长。那是因为如果收入增长可以忽略不计,而且从来没有盈利,就很难确信一家公司能否实现可持续发展。

In the last three years Liaoning OxiranchemInc saw its revenue shrink by 19% per year. That means its revenue trend is very weak compared to other loss making companies. On the face of it we'd posit the share price fall of 12% compound, over three years is well justified by the fundamental deterioration. The key question now is whether the company has the capacity to fund itself to profitability, without more cash. The company will need to return to revenue growth as quickly as possible, if it wants to see some enthusiasm from investors.

在过去的三年中,辽宁OxiRancheminc的收入每年减少19%。这意味着与其他亏损公司相比,其收入趋势非常疲软。从表面上看,我们认为股价在三年内复合下跌12%,这完全是基本面恶化所证明的。现在的关键问题是,公司是否有能力在没有更多现金的情况下为自己筹集资金以实现盈利。该公司要想看到投资者的热情,就需要尽快恢复收入增长。

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

您可以在下图中看到收入和收入随时间推移而发生的变化(点击图表查看确切值)。

earnings-and-revenue-growth
SZSE:300082 Earnings and Revenue Growth April 30th 2024
SZSE: 300082 2024年4月30日收益和收入增长

You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.

您可以在这张免费的交互式图片中看到其资产负债表如何随着时间的推移而增强(或减弱)。

What About The Total Shareholder Return (TSR)?

那么股东总回报(TSR)呢?

We've already covered Liaoning OxiranchemInc's share price action, but we should also mention its total shareholder return (TSR). The TSR attempts to capture the value of dividends (as if they were reinvested) as well as any spin-offs or discounted capital raisings offered to shareholders. Its history of dividend payouts mean that Liaoning OxiranchemInc's TSR, which was a 37% drop over the last 3 years, was not as bad as the share price return.

我们已经报道了辽宁OxiRancheminc的股价走势,但我们还应该提及其股东总回报率(TSR)。股东总回报率试图捕捉股息(就好像它们被再投资一样)以及向股东提供的任何分拆或折扣资本筹集的价值。其股息支付历史意味着辽宁Oxirancheminc的股东总回报率为37% 下降 在过去的3年中,没有股价回报那么糟糕。

A Different Perspective

不同的视角

While the broader market lost about 11% in the twelve months, Liaoning OxiranchemInc shareholders did even worse, losing 34%. However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 2% per year over five years. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. For example, we've discovered 3 warning signs for Liaoning OxiranchemInc that you should be aware of before investing here.

尽管整个市场在十二个月中下跌了约11%,但辽宁Oxirancheminc股东的表现甚至更糟,跌幅为34%。但是,可能只是股价受到了更广泛的市场紧张情绪的影响。如果有很好的机会,可能值得关注基本面。遗憾的是,去年的业绩结束了糟糕的表现,股东在五年内每年面临2%的总亏损。我们意识到罗斯柴尔德男爵曾说过,投资者应该 “在街头流血时买入”,但我们警告说,投资者应首先确保他们购买的是高质量的企业。尽管市场状况可能对股价产生的不同影响值得考虑,但还有其他因素更为重要。例如,我们发现了辽宁Oxirancheminc的3个警告信号,在投资这里之前,你应该注意这些信号。

But note: Liaoning OxiranchemInc may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).

但请注意:辽宁OxiranCheminc可能不是最值得买入的股票。因此,来看看这份过去盈利增长(以及进一步增长预测)的有趣公司的免费清单。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

请注意,本文引用的市场回报反映了目前在中国交易所交易的股票的市场加权平均回报。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发